NETs and endocrine tumours

LBA41 - Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC)

Thomas Walter, et al.


Nivo+Ipi only reached the primary endpoint in 2nd/3rd line NECs pts with acceptable toxicity.


1098O - Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)

Maria Carmen Riesco-Martinez, et al. 


Preliminary results show promising activity of adding Nivolumab to CT as first-line therapy for G3 NENs, with DCR of 84% and greater ORR than benchmark studies. Nivolumab did not significantly increase the toxicity profile of standard CT. Final survival results require further follow-up and translational studies are ongoing.


1096O - Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study

Dieter Horsch, et al.


SPINET, the largest prospective study to date with a SSA in SSTR-positive BP-NETs, suggests that LAN 120 mg could be an appropriate treatment option, especially for TC.


1097O - The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs

Rocio Garcia-Carbonero, et al.


Axitinib demonstrated a significant improvement in PFS in combination with octreotide LAR in pts with advanced progressive G1-2 extra-pancreatic NETs as per independent radiological assessment blinded to treatment allocation, with a tolerable safety profile.